Today it was reported that the EVP, Global R & D of Omnicell (OMCL), Jorge Taborga, exercised options to sell 19,796 OMCL shares at $1132.54 a share, for a total transaction value of $1.66M.
Following Jorge Taborga’s last OMCL Sell transaction on August 08, 2017, the stock climbed by 33.1%. In addition to Jorge Taborga, 6 other OMCL executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Omnicell’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $212 million and quarterly net profit of $14.79 million. In comparison, last year the company earned revenue of $198 million and had a net profit of $24.29 million. OMCL’s market cap is $3.39B and the company has a P/E ratio of 91.22. Currently, Omnicell has an average volume of 290.2K.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy OMCL with a $91 price target. Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $82.33, reflecting a -1.9% downside.
The insider sentiment on Omnicell has been negative according to 83 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omnicell, Inc. engages in the provision of medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions. It operates through Automation & Analytics and Medication Adherence segments.